transforming mcl management guidance on selecting and using btki platforms as first line therapy
Published 1 month ago • 122 plays • Length 54:53Download video MP4
Download video MP3
Similar videos
-
59:49
rebooting the btk inhibitor sequence in mcl
-
1:26:59
transforming care with btk inhibitors in cll
-
1:32
selecting btk inhibitors for patients with mcl
-
1:02:27
personalized treatment with emerging btk inhibitor options in cll/sll and mcl
-
1:25:33
customizing care in cll with btk inhibitors
-
53:40
finding treatment synergy in cll
-
0:57
immunotherapeutic approaches for mcl patients who progress following btki treatment
-
4:11
cll: practical advice on selecting and managing therapy
-
50:02
exploring the rationale, results, and real-world clinical potential of btki in the management of ms
-
1:03:56
reviving the btk target & treatment sequencing in mcl
-
32:51
part 2 - how do i use btki for cll management? - dr. nitin jain, usa
-
1:29:05
btk inhibitors in cll: evidence-informed therapy selection, safety, and sequential care
-
1:49
patient selection for btk inhibitors
-
49:28
btk inhibitors for cll and mcl: what the latest data mean for our patients
-
1:03
advancements in mcl treatment
-
1:47
challenges in using car-t therapy & btk inhibitors in patients with r/r mcl
-
1:46
btk inhibitors continue to improve survival in mantle cell lymphoma
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll